Frequently Asked Questions about Radiopharm Theranostics Limited (RADX)

Name: Radiopharm Theranostics Limited (RADX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Radiopharm Theranostics Limited (RADX) do?

Accepted Answer

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202,...

Question 2

Is Radiopharm Theranostics Limited (RADX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of RADX reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if RADX fits their risk profile.

Question 3

What is the current P/E ratio for RADX?

Accepted Answer

As of the latest trading session, Radiopharm Theranostics Limited (RADX) has a trailing P/E ratio of -1.12.

Question 4

Who is the CEO of Radiopharm Theranostics Limited?

Accepted Answer

The current Chief Executive Officer of Radiopharm Theranostics Limited is Riccardo Canevari.

Question 5

What was RADX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Radiopharm Theranostics Limited reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022) respectively.

Question 6

Does RADX pay a dividend?

Accepted Answer

Radiopharm Theranostics Limited does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does RADX have?

Accepted Answer

In its latest reporting period, Radiopharm Theranostics Limited generated $-0.04B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of Radiopharm Theranostics Limited?

Accepted Answer

The Price-to-Book (P/B) ratio for Radiopharm Theranostics Limited (RADX) is currently 0.96.

Question 9

What is the Price-to-Sales (P/S) ratio of RADX?

Accepted Answer

Based on trailing twelve-month data, Radiopharm Theranostics Limited (RADX) trades at a Price-to-Sales (P/S) ratio of 2.19.

Question 10

What is Radiopharm Theranostics Limited's Return on Equity (ROE)?

Accepted Answer

Radiopharm Theranostics Limited (RADX) has a Return on Equity (ROE) of -105.17%, representing its profitability relative to shareholder equity.